Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 2/20 | 0.43 |
| ▸ | MAOB | P27338 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HTR6 | P50406 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9773035 | 0.85 | MAOA (0.41) | MAOAMAOBGAANPSR1NPC1 | |
| SCHEMBL7217002 | 0.82 | MAOA (0.45) | MAOAMAOBGAANPSR1NPC1 | |
| SCHEMBL10350240 | 0.82 | MAOA (0.38) | MAOAMAOBGAANPSR1 | |
| SCHEMBL295051 | 0.81 | MAOA (0.43) | MAOAMAOBGAANPSR1NPC1 | |
| SCHEMBL9935109 | 0.81 | MAOA (0.43) | MAOAMAOBGAANPSR1NPC1 | |
| SCHEMBL4206535 | 0.81 | MAOA (0.43) | MAOAMAOBGAANPSR1NPC1 | |
| SCHEMBL8663951 | 0.79 | AKR1B1 (0.38) | MAOAMAOBGAANPSR1LMNA | |
| SCHEMBL295013 | 0.78 | MAOA (0.41) | MAOAMAOBGAANPSR1NPC1 | |
| SCHEMBL10645704 | 0.78 | MAOA (0.41) | MAOAMAOBGAANPSR1NPC1 | |
| SCHEMBL8972473 | 0.77 | MAOA (0.39) | MAOAMAOBGAANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1737847-A2 | NEBIVOLOL AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS, PROCESS FOR PREPARATION AND PHARMACEUTICAL COMPOSITIONS OF NEBIVOLOL | Torrent Pharmaceuticals Ltd (IN) | 2007-01-03 | — | — | EP | claimed |
| WO-2006025070-A2 | NEBIVOLOL AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS, PROCESS FOR PREPARATION AND PHARMACEUTICAL COMPOSITIONS OF NEBIVOLOL | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-03-09 | — | — | WO | claimed |
| EP-0334429-A1 | Agents for lowering the blood pressure | JANSSEN PHARMACEUTICA N.V. (BE) | 1989-09-27 | — | — | EP | claimed |
| EP-0052731-B1 | CHROMAN DERIVATIVES AND METHOD FOR THEIR PREPARATION | BASF Aktiengesellschaft (DE) | 1985-04-17 | — | — | EP | claimed |
| EP-0052731-A1 | Chroman derivatives and method for their preparation | BASF Aktiengesellschaft (DE) | 1982-06-02 | — | — | EP | claimed |
| EP-2236510-A1 | PROCESS FOR ISOLATION OF A MIXTURE OF RRRS AND SSSR CONFIGURATIONS OF NEBIVOLOL INTERMEDIATES | Shanghai Modern Pharmaceutical Co., Ltd. (CN) | 2010-10-06 | — | — | EP | disclosed |
| EP-1940441-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | Microbia, Inc. (US) | 2008-07-09 | — | — | EP | disclosed |
| WO-2007022531-A9 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | MICROBIA INC (US) | 2007-04-19 | — | — | WO | disclosed |
| WO-2007022531-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | MICROBIA, INC. (US) | 2007-02-22 | — | — | WO | disclosed |
| EP-1742939-A2 | NOVEL ALKYNE COMPOUNDS EXHIBITING AN MCH ANTAGONISTIC EFFECT AND DRUGS CONTAINING SAID COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-01-17 | — | — | EP | disclosed |
| EP-1737847-A2 | NEBIVOLOL AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS, PROCESS FOR PREPARATION AND PHARMACEUTICAL COMPOSITIONS OF NEBIVOLOL | Torrent Pharmaceuticals Ltd (IN) | 2007-01-03 | — | — | EP | disclosed |
| WO-2006025070-A2 | NEBIVOLOL AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS, PROCESS FOR PREPARATION AND PHARMACEUTICAL COMPOSITIONS OF NEBIVOLOL | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-03-09 | — | — | WO | disclosed |
| US-20050267120-A1 | Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-12-01 | — | — | US | disclosed |
| WO-2005100285-A2 | NOVEL ALKYNE COMPOUNDS EXHIBITING AN MCH ANTAGONISTIC EFFECT AND DRUGS CONTAINING SAID COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-10-27 | — | — | WO | disclosed |
| EP-0334429-A1 | Agents for lowering the blood pressure | JANSSEN PHARMACEUTICA N.V. (BE) | 1989-09-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050267120-A1 | Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds | MCHR1, GPR119, MCHR2 | MAOA 642/4885MAOB 420/4885GAA 684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.